Clinical Trial Update: Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma [Phase 2, Phase 3]

View source ↗

Summary

Assesses the efficacy of adding omalizumab as an add-on therapy for minority patients with moderate-to-severe asthma in Phase 2 and Phase 3 trials. The document…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: DiMango, Emily, M.D. | Conditions: Asthma | Phase 2, Phase 3 | Status: COMPLETED